1/20 Confidential Updated: Jan 2014 The partner in your drug discovery, bridging the gap between R&D and clinical applications I. Major Activity Cellvax SAS, French SME founded in 2001, is a service company (CRO) which provides complete preclinical innovating services allowing accelerating the drug development process for unmet needs related to severe human diseases, mainly in Oncology and Osteoarthritis fields. II. Mission Cellvax’s main expertise: in vitro testing, original animal models in Oncology and Osteoarthritis fields, both subcutaneous (S.C.) and orthotopic tumor models, induced and spontaneous Osteoarthritis models, toxicity, bio-distribution, PK/PD studies, in vivo imaging, histological analysis, etc., allowing speeding up the development of your drug candidates and exploring their maximum potential and mechanism of actions. Cellvax, SAS. Bâtiment Marcenac, aile Est, Ecole Nationale Vétérinaire d’Alfort ; 7, avenue du Général de Gaulle ; 94704 Maisons-Alfort cedex, France. Phone: 33 (0) 1 43 76 32 65; Mobile: 33 (0) 6 71 43 47 51; Fax: 33 (0) 1 43 76 32 65. E-mail: <[email protected]>; Web site: <www.cellvax-pharma.com> 2/20 Confidential Cellvax’s competitive advantages: networking, Original animal models in rodents & non-rodents (Mice, Rats, Hamsters, Guinea pigs, Rabbits, Cats, Dogs, …); Numerous technical platforms, Reactivity, Confidentiality, Reliability, Track records of our founder team, etc. Cellvax positioning in drug discovery process: Clinical trails Candidate molecule identification Pre-clinical trials Phase I Phase II Phase III Phase IV Commercialization Drug surveillance Preclinical tests Our services allow speeding up the development of your drug candidates, valorizing drug potential and decreasing the cost of your drug development. III. Cellvax presentation Cellvax, founded in 2001, is a fast-growing technology-driven pre-clinical service company focalizing on oncology and on Osteoarthritis. Today, Cellvax directly employs and through R&D collaborations motivated and differently skilled scientists and engineers, working in interdisciplinary teams on several innovative products. Since its foundation, Cellvax has significantly progressed as a service company, especially in different cancer models in mice, angiogenesis models in vitro and in vivo. Recently, we have developed several other models such as Oncology, Osteoarthritis, Parkinson diseases, Diabetes, AMD, etc. in order to fully satisfy Cellvax, SAS. Bâtiment Marcenac, aile Est, Ecole Nationale Vétérinaire d’Alfort ; 7, avenue du Général de Gaulle ; 94704 Maisons-Alfort cedex, France. Phone: 33 (0) 1 43 76 32 65; Mobile: 33 (0) 6 71 43 47 51; Fax: 33 (0) 1 43 76 32 65. E-mail: <[email protected]>; Web site: <www.cellvax-pharma.com> 3/20 Confidential the specific needs of our customers. We have concluded numerous contracts with different companies in France, in Europe and in the world. Here is a brief summary of Cellvax since its foundation in 2001: 1er French Government Grant, OSEO EU EUREKA EU FP-7 projects New facility, Multiple animal species 3. Consolidation & Expansion 2. Strong growth Early phases clinical trials Foundation 2001 1. Initiation 2004 2006 2007 2008 2010 Cellvax is always ready to adapt to the market evolution and to satisfy its customers’ specific needs all over the world. Cellvax is strongly willing to develop and enhance its national and international collaboration with public laboratories, biotechnological companies and pharmaceutical companies in cancer field. In this regard, Cellvax is also actively involved in different European collaborative programs. In 2007, Cellvax has successfully launched an EUREKA project in cancer field named “Oligoclonics Σ!3942” entitled “An innovative technology and product platform for improved antibody therapeutic” with another French partner (anticancer center: Institut Gustave Roussy) and three partners from Holland. Under this project, Cellvax has alrealy demonstrated its coordination and managerial Cellvax, SAS. Bâtiment Marcenac, aile Est, Ecole Nationale Vétérinaire d’Alfort ; 7, avenue du Général de Gaulle ; 94704 Maisons-Alfort cedex, France. Phone: 33 (0) 1 43 76 32 65; Mobile: 33 (0) 6 71 43 47 51; Fax: 33 (0) 1 43 76 32 65. E-mail: <[email protected]>; Web site: <www.cellvax-pharma.com> 4/20 Confidential skills within a European collaborative R&D environment and through its relation with the Eureka Office and French funding body. In 2011, Cellvax has successfully obtained a 2nd FP-7 grant “Piedpiper” for a total amount of 2.4 millions €. IV. Main Advantages Cellvax’s project is founded by scientists and experts. Cellvax’s team is composed of people who have a strong professional complementary which gives a scientific, medical and industrial dimension of the company. Our services are built on these advantages: A. Present knowledge of Cellvax’s team The new knowledge progress and the technological explosion in cellular and molecular biology and genomics have helped tumors molecular detailed analysis. Cellvax’s team totally controls these knowledges and the related Cellvax, SAS. Bâtiment Marcenac, aile Est, Ecole Nationale Vétérinaire d’Alfort ; 7, avenue du Général de Gaulle ; 94704 Maisons-Alfort cedex, France. Phone: 33 (0) 1 43 76 32 65; Mobile: 33 (0) 6 71 43 47 51; Fax: 33 (0) 1 43 76 32 65. E-mail: <[email protected]>; Web site: <www.cellvax-pharma.com> 5/20 Confidential technologies in this field. Our services allow developing a therapeutic approach which is more suitable for each patient and each biological target. In order to expand our offers, Cellvax has recently moved to a new laboratory facility, on the border of Paris, inside “Ecole Nationale Vétérinaire de Maisons Alfort” (ENVA). The ENVA is one of the oldest and largest veterinary universities in Europe, created in 1766 just on the border of Paris, with an easy access by subway. In this new facility, Cellvax is able to provide a number of new services especially with large animals (Mice, Rats, Hamsters, Guinea pigs, Rabbits, Cats, Dogs, …), Numerous technical platforms, in vivo imaging platforms, MRI, Scanner, Scintigraphy radio-labeled compounds, etc. In consequence, Cellvax is able to provide the services not only in small animals, but also in large animals in a more efficient way. B. Our multidisciplinary expertise Cellvax has a network of collaborations and is able to analyze tumoral and blood biopsies in molecular biology. This network is composed of chemists, molecular and cellular oncologists, immunologists, doctors, pharmacologists… Cellvax, SAS. Bâtiment Marcenac, aile Est, Ecole Nationale Vétérinaire d’Alfort ; 7, avenue du Général de Gaulle ; 94704 Maisons-Alfort cedex, France. Phone: 33 (0) 1 43 76 32 65; Mobile: 33 (0) 6 71 43 47 51; Fax: 33 (0) 1 43 76 32 65. E-mail: <[email protected]>; Web site: <www.cellvax-pharma.com> 6/20 Confidential V. Preclinical Study Services 1). Anti-proliferative tests in vitro Cellvax proposes in their services to realize different tests in vitro on established cell lines or primary cultures: anti-proliferative tests, PK study, cell cycle, apoptosis, etc. This technique allows at first to evaluate the anti-tumoral potential of drug candidates. Our company has also an important expertise in a three-dimensional cell culture method of cancer cells called nodules which has the advantage of maintaining some of the in vivo cellular architecture and interactions. 2). Original Nodule model in vitro For anti-cancer drug validation studies in vitro and in vivo, several models have been developed and used. Here, Cellvax has successfully developed a new model which is between in vitro and in vivo model, called “the Nodule model in three dimensions”. We believe that this model could be an ideal tool in anticancer drug discovery studies. A three-dimensional cell co-culture method is presented where cancer cells can be maintained alone or combined with other cell types in long-term culture in order to reconstitute some of the interactions between the different cell elements in tumors in vivo. The cells are accumulated by centrifugation to form “nodules” which are cultivated on a semi-solid agar medium at medium / air interface. The nodules are not only cell aggregates, they are able to develop morphological and functional differentiation often lost in mono-layer cell culture conditions. Also, a different sensitivity to chemical and physical anti-tumoral treatments has been demonstrated. Studies on short-term and long-term effects of anti-cancer treatments are possible. Cellvax, SAS. Bâtiment Marcenac, aile Est, Ecole Nationale Vétérinaire d’Alfort ; 7, avenue du Général de Gaulle ; 94704 Maisons-Alfort cedex, France. Phone: 33 (0) 1 43 76 32 65; Mobile: 33 (0) 6 71 43 47 51; Fax: 33 (0) 1 43 76 32 65. E-mail: <[email protected]>; Web site: <www.cellvax-pharma.com> 7/20 Confidential 3). Animal cancer models Today, cancers still remain a major public health problem in the world, especially in industrialized countries. Cancer is projected to become the leading cause of death worldwide in the year 2010, according to a new report the International Agency for Research on Cancer (IARC), a division of the World Health Organization (WHO). Furthermore, apart from being a public health burden, the economical facts are as impressive. The costs for cancer care in the EU sums 54 billion € and the global oncology market is around 40 millions € with more than 150 cancer drugs approved for its use across the world. We propose not only subcutaneous tumor models but also original orthotopic tumor models in animal in which we induce lung cancer, colon cancer, pancreas cancer, prostate cancer, breast cancer, gastric cancers, brain tumors, leukemia… The orthotopic tumor models present a degree of complexity superior to classical pathological models. The implantation of tumor cells in their original tissue allows development of tumor comparable to human tumor with production of metastasis in a few weeks. Moreover, the same time course of development of tumor and metastasis than human is observed in animal. The tumor development can be induced in animals either by injecting human and/or rodent tumor cells or by grafting freshly operated human tumors in animals. Cellvax, SAS. Bâtiment Marcenac, aile Est, Ecole Nationale Vétérinaire d’Alfort ; 7, avenue du Général de Gaulle ; 94704 Maisons-Alfort cedex, France. Phone: 33 (0) 1 43 76 32 65; Mobile: 33 (0) 6 71 43 47 51; Fax: 33 (0) 1 43 76 32 65. E-mail: <[email protected]>; Web site: <www.cellvax-pharma.com> 8/20 Confidential Metastasis Blood vessel The tumor development can be induced in animals either by injecting human and/or rodent tumor cells or by grafting freshly operated human tumors in animals. In vivo perfusion Surgical operation with specific injections Stereotaxic injection Injectin into carotine Cellvax, SAS. Bâtiment Marcenac, aile Est, Ecole Nationale Vétérinaire d’Alfort ; 7, avenue du Général de Gaulle ; 94704 Maisons-Alfort cedex, France. Phone: 33 (0) 1 43 76 32 65; Mobile: 33 (0) 6 71 43 47 51; Fax: 33 (0) 1 43 76 32 65. E-mail: <[email protected]>; Web site: <www.cellvax-pharma.com> 9/20 Confidential 4). Angiogenic tests in vitro & in vivo Angiogenesis plays an important role in the tumoral development. Cellvax proposes pro- or anti-angiogenic tests. In this in vitro model, human umbilical vein endothelial cells are coated on microcarrier beads then the blood capillaries formation is analysed. In order to exploit the anti-angiogenic potential of drug candidates, our test is essential for biotechnology societies which develop these drug candidates. An in vivo original model is also available and consists on a Matrigel implantation in mouse and on a measure of the drug candidates’ effects on the microvessels formation. Fibrin gel 5). Tumoral invasion tests in vitro Metastasis formation is the most deleterious mechanism in the tumor formation. Cellvax proposes in vitro tests which allow to measure the anti-metastatic potential of drug candidates. These techniques allow to study the intravasation and extravasation potentials of tumor cells through endothelium. The intravasation of tumor cells through endothelium is measured by a co-culture technique. Tumor cells were cultured on a micropore membrane in the top part of the chamber and endothelial cells were cultured in the low part of the chamber. This technique consists on measuring the number of tumor cells which have migrated through the micropore membrane toward to endothelial cells. The extravasation technique consists on measuring under flow tumor cells adhesion on endothelial cells. Cellvax, SAS. Bâtiment Marcenac, aile Est, Ecole Nationale Vétérinaire d’Alfort ; 7, avenue du Général de Gaulle ; 94704 Maisons-Alfort cedex, France. Phone: 33 (0) 1 43 76 32 65; Mobile: 33 (0) 6 71 43 47 51; Fax: 33 (0) 1 43 76 32 65. E-mail: <[email protected]>; Web site: <www.cellvax-pharma.com> 10/20 Confidential 6). Tumoral invasion tests in vivo Cellvax proposes analyses of tumor cells distribution in all animals. Stained tumor cells can be detected, counted and located in alive animals. This technique allows determining the anti-metastatic potential of drug candidates. 7). Orthotopic tumor models Many studies have tested anti-proliferative effect and cancer specificity of drug candidates in vitro. According to NCI recommendations, selected in vitro molecules must demonstrate their efficiency on xenografted tumor cell lines in nude mice, before pre-clinical and clinical development. In this model, tested molecules are often administered intra-peritonealy. Efficiency of drug candidates is determined based on the tumor growth inhibition after treatment, or total tumor regression. It has been established that subcutaneous tumors in mice don’t metastasize and develop around the injection. Further studies shown that the subcutaneous tumor chemotherapy sensitivity can be modified. To solve this problem, orthotopic xenografts (in origin site) in mice have been fully developed at Cellvax. The orthotopic tumor model presents a superior complexity degree compared to classical models. In fact, tumor cell lines implantation in their origin site allows the tumoral development comparable to human tumoral development with metastases formation in a few weeks. This model also allows mimicking sequential tumor development. The primary tumor develops in its origin site and metastasizes at distance. The metastasis formation is induced with the similar order as in human. Cellvax proposes to realise orthotopic models for your drug validation studies in breast cancer, colon cancer, lung cancer, pancreas cancer, kidney cancer, prostate cancer, melanoma, glioblastoma, … Cellvax, SAS. Bâtiment Marcenac, aile Est, Ecole Nationale Vétérinaire d’Alfort ; 7, avenue du Général de Gaulle ; 94704 Maisons-Alfort cedex, France. Phone: 33 (0) 1 43 76 32 65; Mobile: 33 (0) 6 71 43 47 51; Fax: 33 (0) 1 43 76 32 65. E-mail: <[email protected]>; Web site: <www.cellvax-pharma.com> 11/20 Confidential Lung metastasis induced by human breast tumor cells in mice. Metastasis Blood vessel Lung metastasis induced by mouse breast cancer cells 4T1 in mice. Cellvax, SAS. Bâtiment Marcenac, aile Est, Ecole Nationale Vétérinaire d’Alfort ; 7, avenue du Général de Gaulle ; 94704 Maisons-Alfort cedex, France. Phone: 33 (0) 1 43 76 32 65; Mobile: 33 (0) 6 71 43 47 51; Fax: 33 (0) 1 43 76 32 65. E-mail: <[email protected]>; Web site: <www.cellvax-pharma.com> 12/20 Confidential 8). Syngeneic tumor models in animals The role of the host immune response in combating neoplastic growth has been extensively studied over the past several years. In order to investigate the antitumor actiovity of a test compound in a closer situation to human, it is extremely usual to employ syngeneic immuno-competent animal tumor models for the preclinical evaluation of test agents. For this purpose, we have developed different syngeneic tumor models: - Leukemia: Leukemia FBL-3 cells in C57/BL6 mice; - Melanoma: B16F10 tumor cells in C57/BL6 mice; - Bladder cancer: MB49 tumor cells in C57/BL6 mice; - Prostate cancer: TRAMP-C2 tumor cells in C57/BL6 mice; - Pancreatic tumor: PANC02 tumor cells in C57/BL6 mice; - Kidney cancer: RENCA tumor cells in Balb/c mice; - Fibrosarcoma: CSA1M tumor cells in Balb/c mice; - Breast cancer: 4T1 tumor cells in Balb/c mice; - Brain tumor: 9L in Fisher rats; - Colon cancer: CT26 tumor cells in Balb/c mice; - Pancreatic tumor: PC-1.0 tumor cells in Syrian hamsters; - Mastocytoma: P-815 cells in DBA/2; - Hepatic Cancer: Hepa 1-6 cells in C57/BL6 mice, and Hepa129 cells in C3H mice; - Etc. Cellvax, SAS. Bâtiment Marcenac, aile Est, Ecole Nationale Vétérinaire d’Alfort ; 7, avenue du Général de Gaulle ; 94704 Maisons-Alfort cedex, France. Phone: 33 (0) 1 43 76 32 65; Mobile: 33 (0) 6 71 43 47 51; Fax: 33 (0) 1 43 76 32 65. E-mail: <[email protected]>; Web site: <www.cellvax-pharma.com> 13/20 Confidential 9). Original drug-resistant tumor models in vitro & in vivo Intrinsic or acquired tumor-mediated drug resistance is a major clinical problem that can result in the lack of tumor response to chemotherapy. In order to continuously improve the quality and the originality of Cellvax’s oncology services, we have successfully established several drug-resistant tumor models: lung cancer, pancreatic tumor, ovary cancer, etc. 10). In vivo imaging in alive animals For these studies, we can propose several imaging technologies: PET Scan, Scanner, X-ray, MRI, Bioluminescence. The new technology, PET (Positron Emission Tomography) Scan, by labeling with 18FDG (Fluoro-Deoxy-dGlucose), allows to observe phenomenon (micro-metastasis formation, drug biodistribution, etc) in the same alive animal at different time points without sacrificing animals. Metastasis 11). Primary tumor cells Testing your promising compounds by using human primary tumor cells is the closest way to the real clinical situation. These data would be very useful for your future clinical trials. The established tumor cell lines, after numerous passages in vitro, might loose their initial biological characteristics. In contrast, Cellvax, SAS. Bâtiment Marcenac, aile Est, Ecole Nationale Vétérinaire d’Alfort ; 7, avenue du Général de Gaulle ; 94704 Maisons-Alfort cedex, France. Phone: 33 (0) 1 43 76 32 65; Mobile: 33 (0) 6 71 43 47 51; Fax: 33 (0) 1 43 76 32 65. E-mail: <[email protected]>; Web site: <www.cellvax-pharma.com> 14/20 Confidential these primary tumor cells (freshly established from human biopsies) conserve these biological characteristics and could be an ideal tool in anti-cancer studies. 12). More relevant tumor models - Direct implantation of human tumor biopsies in mice To reconstitute tumor micro-environment; To be as close as possible to human tumors; Tumors are maintained from mice to mice, without using cell culture system. - Non-rodent cancer models, spontaneous tumors 13). Osteoarthritis animal models Knee osteoarthritis (OA) affects an estimated 27 million Americans (Lawrence R.C., et al. Part II,” Arthritis & Rheumatism, vol. 58, no. 1, pp. 26–35, 2008). Despite extensive research seeking therapeutic interventions for this disease, there are still no proven disease-modifying treatments for osteoarthritis. With the number of total knee arthroplasties growing each year, this is a rapidly expanding public health epidemic, both in terms of health-related quality of life and financial expenditure (Losina E, et al. The Journal of Bone & Joint Surgery A, vol. 94, no. 3, pp. 201 – 207, 2012). For this disease, Cellvax can propose two types of animal models: Induced Osteoarthritis (OA) Animal Models: - Anterior Cruciate Ligament Transection (ACLT) in rabbits, rats, dogs, … ; Meniscectomy; Patellectomy; Immobilization; Ovariectomy: Postmenopausal OA; Enzymatic / chemically induced OA; Others, … Cellvax, SAS. Bâtiment Marcenac, aile Est, Ecole Nationale Vétérinaire d’Alfort ; 7, avenue du Général de Gaulle ; 94704 Maisons-Alfort cedex, France. Phone: 33 (0) 1 43 76 32 65; Mobile: 33 (0) 6 71 43 47 51; Fax: 33 (0) 1 43 76 32 65. E-mail: <[email protected]>; Web site: <www.cellvax-pharma.com> 15/20 Confidential Spontaneous Osteoarthritis (OA) Animal Models: - Mouse (DBA/1, STR/ORT, C57BL/6, C57); - Guinea pig (Hartley, Duncan-Hartley); - Others, … 14). Toxicity studies in vivo (both rodent and non-rodent) A complete toxicity experiment can be proposed at Cellvax in both rodent and nonrodents: - Acute toxicity in mice, animals; Sub-acute toxicity in animals; Chronic toxicity in animals; MTD (Maximum Tolerated Dose) with single dose and/or repeated doses; “Abnormal toxicity” in two animal species according to European guidelines; Complete blood count (CBC). (Total blood analysis: Red cells; White cells; Platelets; Hemoglobin) and Chemistry profile (Alanine aminotransferase (ALT); Aspartate aminotransferase (AST); Alkaline phosphatase (ALP); Creatinine kinase; Glucose); - Monitoring: animal body weight, behavior, eventual death; - Hematological and biochemical analysis; - Macroscopic observation and histological analysis on main organs. Cellvax, SAS. Bâtiment Marcenac, aile Est, Ecole Nationale Vétérinaire d’Alfort ; 7, avenue du Général de Gaulle ; 94704 Maisons-Alfort cedex, France. Phone: 33 (0) 1 43 76 32 65; Mobile: 33 (0) 6 71 43 47 51; Fax: 33 (0) 1 43 76 32 65. E-mail: <[email protected]>; Web site: <www.cellvax-pharma.com> 16/20 Confidential 15). Bio-distribution and PK studies in vivo (both rodent and nonrodent) In order to understand the pharmacokinetics (PK) of your innovating drugs, we propose a bio-distribution and PK studies in mice, rats, beagle dogs, mini-pigs. At different time points (Typical time points: 30 Min; 1h; 3h; 6h; 12h; 24h; 32h; 48h and 96h), the presence of your drug or its metabolites will be searched and analyzed in different organs (Liver; Spleen; Lung; Heart; Brain; Intestine; Adipose tissues; Skin; Bone; Serum; Urine, etc.). 16). Mechanisms of actions studies - Topoisomerases I & II, required during DNA replication, transcription and homologous recombination; - Cell cycle analysis Cells, stained with BrdU (Bromodeoxyuridin) and IP (iodide propidium); - Specific biomarkers by ICH Proliferation marker, Ki-67; angiogenesis marker, CD-31, T cell infiltrations in tumors (CD4+ or CD8+), hypoxia, etc.; - Apoptosis analysis: Cells labeled with Annexin V and IP. Doublestained cells analyzed by FACScan. 17). Complete histological analysis and/or with experts’ interpretations - Tissues fixation in 4% Formalin; Frozen tissues; Paraffin-embedded or frozen sections; H&E and/or immuno-staining. Cellvax, SAS. Bâtiment Marcenac, aile Est, Ecole Nationale Vétérinaire d’Alfort ; 7, avenue du Général de Gaulle ; 94704 Maisons-Alfort cedex, France. Phone: 33 (0) 1 43 76 32 65; Mobile: 33 (0) 6 71 43 47 51; Fax: 33 (0) 1 43 76 32 65. E-mail: <[email protected]>; Web site: <www.cellvax-pharma.com> 17/20 Confidential Paraffin-embedding Put into cassettes Microtome cutting Immuno-staining: T cell infiltration stained with CD4 & CD8 antibodies. Necrotic area inside tumors, with H&E staining 18). Other specific studies upon request Cellvax is also able to provide customized studies according to your specific needs in order to fully satisfy the specific needs of our customers. Cellvax, SAS. Bâtiment Marcenac, aile Est, Ecole Nationale Vétérinaire d’Alfort ; 7, avenue du Général de Gaulle ; 94704 Maisons-Alfort cedex, France. Phone: 33 (0) 1 43 76 32 65; Mobile: 33 (0) 6 71 43 47 51; Fax: 33 (0) 1 43 76 32 65. E-mail: <[email protected]>; Web site: <www.cellvax-pharma.com> 18/20 Confidential - HSV-1 and HSV-2 infection models in mice; - Diabetic models: - In vitro models; - In vivo model for Type I diabetes; - In vivo model for Type II diabetes. - Parkinson diseases: - In vitro models; - In vivo models. - Ascite production: Ascite production in mice by administration of the incomplete Freund's adjuvant. VI. Why contact us? Expertise of our founder and operational teams; Complementary and extensive biological tests; Reactivity and efficiency of services; Confidentiality and experimental procedures with Quality Insurance manager; State of the art animal facility with rodents and non-rodents; Access to a network of public and private laboratories; Continuous improvement of our tests in order to be more competitive; Our services allow to speed up the development of your drug candidates; Our services allow to valorize drug potential in several pathologies; Our services allow decreasing your cost of drug development; Support of external marketing. Cellvax, SAS. Bâtiment Marcenac, aile Est, Ecole Nationale Vétérinaire d’Alfort ; 7, avenue du Général de Gaulle ; 94704 Maisons-Alfort cedex, France. Phone: 33 (0) 1 43 76 32 65; Mobile: 33 (0) 6 71 43 47 51; Fax: 33 (0) 1 43 76 32 65. E-mail: <[email protected]>; Web site: <www.cellvax-pharma.com> 19/20 Confidential VII. Business development The will to collaborate Cellvax is a preclinical service company with strong expertise mainly in Oncology and Osteoarthritis fields. Our interactive collaborations allow accelerating the development of your drug candidates. Cellvax has a strong will to collaborate with public laboratories, biotech and/or with pharmaceutical companies which develop novel compounds. These collaborations could be very enriching and allow speeding up the development of your drug candidates. Partnering strategy Cellvax is also seeking to establish close collaboration and/or partnership to develop or co-develop innovating compounds with a greater speed and less cost. VIII. State of the art animal facility Cellvax, SAS. Bâtiment Marcenac, aile Est, Ecole Nationale Vétérinaire d’Alfort ; 7, avenue du Général de Gaulle ; 94704 Maisons-Alfort cedex, France. Phone: 33 (0) 1 43 76 32 65; Mobile: 33 (0) 6 71 43 47 51; Fax: 33 (0) 1 43 76 32 65. E-mail: <[email protected]>; Web site: <www.cellvax-pharma.com> 20/20 Confidential IX. Contact Information E-mail: Phone: Fax: Web site: Mailing address: Cellvax Laboratory facility Bâtiment Marcenac, aile Est, Ecole Nationale Vétérinaire d’Alfort 7, avenue du Général de Gaulle 94704 Maisons Alfort cedex, France. <[email protected]> + 33 (0) 1 43 76 32 65; Mobile: + 33 (0) 6 71 43 47 51. + 33 (0) 1 43 76 32 65. <www.cellvax-pharma.com> Thank you for your attention ! From R&D via animal to man! Cellvax, SAS. Bâtiment Marcenac, aile Est, Ecole Nationale Vétérinaire d’Alfort ; 7, avenue du Général de Gaulle ; 94704 Maisons-Alfort cedex, France. Phone: 33 (0) 1 43 76 32 65; Mobile: 33 (0) 6 71 43 47 51; Fax: 33 (0) 1 43 76 32 65. E-mail: <[email protected]>; Web site: <www.cellvax-pharma.com>